Acimtamig

Phase I trial results from MD Anderson Cancer Center demonstrate 92.9% overall response rate and 66.7% complete response rate in 42 heavily pretreated patients with CD30-positive lymphomas using cord blood-derived NK cells pre-complexed with AFM13.

The FDA has granted traditional approval to acalabrutinib in combination with bendamustine and rituximab for untreated MCL patients ineligible for stem cell transplant.

Affimed, a leader in innate cell engager (ICE®) therapies, is making significant strides in the clinical development of novel treatments for solid and hematologic tumors. With over 500 patients treated, the company has demonstrated clinical efficacy across various indications, leveraging its proprietary IP targeting CD16A on NK cells and macrophages. Affimed's ongoing clinical programs, including AFM24, Acimtamig (AFM13), and AFM28, show promising results in treating advanced/metastatic NSCLC, R/R Classical HL, and R/R CD123+ AML, respectively. The company's innovative approach combines ICE® molecules with NK cell therapy and checkpoint inhibitors to enhance the immune system's ability to fight cancer.

The FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to Affimed's acimtamig and Artiva's AlloNK combination for relapsed/refractory Hodgkin Lymphoma.

Affimed N.V., a leader in innate cell engager (ICE®) technology, is making significant strides in the clinical development of novel therapies targeting solid and liquid tumors. With over 500 patients treated, the company has demonstrated clinical efficacy across various indications, leveraging its proprietary IP targeting CD16A on NK cells and macrophages. Affimed's pipeline includes promising candidates like AFM24, AFM13, and AFM28, each showing potential in addressing significant unmet needs in cancer treatment, particularly in non-small cell lung cancer (NSCLC), Hodgkin lymphoma (HL), and acute myeloid leukemia (AML).